Lerodalcibep not checked

LIB Therapeutics LLC · LIB003

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
2 active
11 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Familial Hypercholesterolemia - Heterozygous, Heterozygous Familial Hypercholesterolemia (HeFH)
Main trialPhase 3
“The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins. The main question\[s\] it aims to answer are: How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety…”In the company’s words, NCT07102511 on ClinicalTrials.gov
Other names
LIB003

Other drugs for Familial Hypercholesterolemia - Heterozygous

All 21 drugs for Familial Hypercholesterolemia - Heterozygous

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Enrolling by invitation 31 Jul 2028 Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
Phase 3Not yet recruiting 31 Jul 2031 Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia
Phase 3Completed 30 Jun 2022 Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product
Phase 3Completed 12 Sep 2022 Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
Phase 3Completed 30 Sep 2022 Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
Phase 3Completed 30 Jul 2023 Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
Phase 3Unknown 15 Nov 2023 Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
Phase 3Unknown 15 Nov 2023 Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction
Phase 3Completed 30 May 2024 Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
Phase 3Unknown 30 Jul 2025 Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
Phase 2Completed 7 Apr 2020 Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lerodalcibep

Following is part of Solo: you see every change to Lerodalcibep the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in